Actively Recruiting
Using Bimatoprost Eye Drops to Treat Graves Orbitopathy by Reducing Eye Bulging
Led by Johns Hopkins University · Updated on 2026-07-16
3
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether Bimatoprost, a topical eye drop commonly used for glaucoma, can reduce periorbital fat and improve eye bulging proptosis in patients with Graves disease. This early phase 1 study focuses on treating Graves ophthalmopathy, a condition causing eye protrusion, by testing this new use of Bimatoprost. Participants apply one drop of Bimatoprost each night to their eye with more pronounced proptosis, while their other eye does not receive the treatment. The study compares the treated eye to the untreated eye to monitor changes. This single-masked trial follows patients over one year to observe treatment effects. During the study, participants will have regular assessments to measure the reduction in periorbital fat and improvement in eye bulging. Researchers will monitor eye changes and any side effects throughout the trial. The main outcome is the degree of fat reduction after one year. The trial is conducted by Johns Hopkins University and lasts until July 2031.
CONDITIONS
Brief Title
Bimatoprost as a Treatment for Graves' Orbitopathy
Research Team
E
Emily Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
